Personalized Treatment Options for Esophageal Cancer Are One Call Away
Call Now
Early, Late-Stage, and Metastatic Esophageal Cancer Treatment
Primary and Adjuvant Treatment Options for all Types and Stages
of Esophageal Cancer
If you have been diagnosed with esophageal cancer, you may be aware of the aggressive nature of this cancer, which
can
quickly spread to the liver, lungs, and other adjoining or distant regions of the body. To comprehensively treat this
aggressive cancer of the upper gastrointestinal tract, at Envita Medical Centers, a world-class integrative center for
precision oncology, we go beyond standard treatments like chemoradiation, radiation therapies, or invasive surgeries,
such as, esophagectomy.
In our clinical experience of over 20 years, utilizing a personalized combination of our innovative immunotherapies
along with several proprietary treatments, such as, CIPI™ and GTFC™, have proved beneficial for patients with early
stage as well as advanced esophageal cancer. Our team of integrative physicians develop personalized treatment plans
based on the latest cancer research from around the world, to strike out the unique causative factors of each
patient’s
esophageal cancer.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Envita’s personalized precision oncology treatments take into account each patient’s esophageal cancer cell biology
and
its microenvironment, to accurately target the disease, while bolstering the patient’s immune system. These
personalized
targeted therapies have been beneficial for several patients, even those with inoperable or high-grade esophageal
squamous cell carcinoma or adenocarcinoma. Our goal is to help patients progress towards a holistic recovery and
sustain
long term remissions, irrespective of the stage or type of their esophageal cancer.
This article covers basic facts about Esophageal Cancer including:
How Envita Overcomes Challenges in Standard Treatment of Esophageal Cancer
Standard treatments often include invasive thoracic surgeries, stent placements for esophageal dilation, exhaustive
chemoradiotherapy regimens, external beam radiations, endoscopic ultrasound (EUS), endoscopic mucosal resection, or
photodynamic therapy. While this treatment selection may seem extensive, there is no guarantee that any treatments
will
work for your specific diagnosis, which explains the poor prognoses of esophageal cancer. To improve overall survival,
we breakaway from the standard treatments dictated by the NCCN (National Comprehensive
Cancer Network) guidelines which are typically followed in conventional cancer specialty healthcare centers and
hospitals across
the country.
According to the National Cancer Institute’s
report based on patient outcomes across standard cancer centers, which typically
follow the NCCN guidelines, the 5-year relative survival rate of esophageal cancer is 20.6%, highlighting the need for
personalized precision oncology treatments.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Precision Oncology is Crucial for a Targeted Esophageal Cancer Treatment
Plan
The handful of patients who receive precision oncology treatments, as per NCCN guidelines, get a watered-down version
of
Envita’s detailed personalized precision oncology esophageal cancer treatment program. At Envita, we investigate many
more factors than standard precision oncology to comprehensively treat the disease, while reducing chances of future
growth or spread.
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
A detailed investigation of each of these parameters could be crucial for understanding the molecular mechanisms
associated with chemotherapeutic drug resistance chemotherapeutic
drug resistance. According to medical
studies, drug resistance represents the major obstacle to getting the maximum therapeutic benefit for patients
with esophageal
cancer since numerous patients are inherently or adaptively resistant to therapeutic agents [1]. To overcome this
obstacle, which in turn leads to further metastases, our expert team of integrative physicians personalize a
treatment
plan for each esophageal cancer patient.
Envita Medical Centers Medical Team
Physicians with MD, MD(h), and NMD medical
licenses, including certified oncologists, and certified interventional radiologists,
striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
Personalized Clinical Trial Approach to Improve Overall Survival
Personalizing a treatment plan on the N-of-1
model potentially helps in improving overall survival, as this single-subject clinical trial determines the optimal or
best intervention for an individual patient using objective data-driven criteria [2]. At Envita, we follow this N-of-1
model to help our patients receive the best possible care for their esophageal cancer, while reducing the chance of
side
effects.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
With standard chemotherapy or radiation therapies, several patients may experience treatment induced strictures in
the
affected part of the esophagus, leading to difficulty in swallowing, which may compel them to depend on feeding tubes
or
undergo further procedures for esophageal dilation. To minimize the risk of such side effects and enhance the efficacy
of treatments, we customize a unique medical blueprint for each patient.
Envita’s customized medical blueprint is designed on a four-step process, which aims towards optimizing quality of
life,
increasing longevity, and reducing toxicity.
Step 1
Genomic Analysis to Custom-Build a Comprehensive Treatment Plan
Envita’s proprietary genomic analysis dissects the unique set of causes responsible for triggering the growth and
proliferation of esophageal cancer in each individual patient. A wide variety of risk factors, such as, smoking,
alcohol
consumption, gastric reflux, a condition called Barrett’s esophagus, or other inherited mutations, could trigger
esophageal cancer, and identifying the potential triggers is critical to custom-building a comprehensive treatment
plan.
Root-cause analysis of cancer is essential to sustain long term remission and Envita’s personalized precision
oncology
program is designed to treat the disease at its core. We take into account extensive genomics, transcriptomics,
proteomics, and metabolomics, while evaluating each patient’s immune system, and other factors, such as, environmental
toxins, molds, and infections, which could potentially contribute to their disease burden.
This genomic analysis helps in understanding the reason behind the
molecular and cellular changes leading up to the varied types and subtypes
of esophageal cancer, with varying grades and degree of disease burden. Due to the lack of this analysis in standard
treatment plans, we often see patients whose previous treatments have failed to yield long term results, as the
potential causes of their disease remained untargeted during their treatment.
According to a medical review, current
molecular and cellular
characterization of types of esophageal cancer should serve as background for
development of new treatment strategies, which is what we are working towards here at Envita [3]. In our clinical
experience, long-term remissions may be attained by addressing the unique set of underlying causative factors
responsible for the esophageal cancer cell mutations in each patient.
Step 2
Immune System Targeting to Reduce Chances of Metastasis or Relapse
Our Ultra Analytes liquid biopsy analyzes and tracks the esophageal cancer cell mutations in real time to
attack the
disease through chemo and immuno targeting. This liquid biopsy provides information about the latest mutations
by
examining the CTCs (Circulating Tumor Cells) collected from a patient’s blood sample.
The CTCs are parts of a growing tumor, which break away from it to enter the patient’s blood stream and spread
the
disease to various parts of the body. Analyzing the CTCs gives us the most current cancer biomarkers, which are
attributes of your specific cancer cell. Armed with this information, our team of physicians are better equipped
to
identify where the cancer is heading and treat it proactively, potentially reducing chances of a metastasis or
relapse.
We go beyond standard immunotherapies, such as PD-L1 and other Immune Checkpoint Inhibitors, to include various
levels
of personalized immunotherapies in every patient’s protocol,
irrespective of their type or stage of esophageal cancer. Medical reports
indicate the potential tumor suppressor role of certain miRNA (microRNA) in esophageal cancer, and Envita’s
proprietary
miRNA gene therapies work to aggressively downregulate oncogenes and upregulate required tumor suppressor genes [4].
These detailed and personalized immunotherapies are aimed at initiating the body’s natural defense against cancerous
cells to possibly halt the growth and spread of the disease.
Step 3
Personalized Drug Design for Specialized Targeted Therapies
In our clinical opinion, a combination of FDA (Food and Drug Administration) approved drugs, repurposed
drugs, and
custom-compounded adjuvants, is key to developing specialized targeted therapies. At Envita, targeted
therapies are not
just a treatment option for esophageal cancer, as our entire approach is precision-targeted to attack each
patient’s
individual esophageal cancer.
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
Adjuvants are add-on supportive care therapies which enhance the body’s immune response to antigens released by
tumors.
These personalized medications can also be utilized as neoadjuvant therapies for debulking tumors in the esophagus or
other parts of the body, before starting the primary treatment for attacking the disease.
We custom compound these medications at our in-house pharmacy using phytotherapeutic,
plant-derived
medications, and other natural agents, which are genetically typed to suit each patient’s specific cancer cell
mutations. This level of personalization increases treatment options for our patients, going beyond the scope of the
limited anti-cancer drugs available on the market.
Even the dosage of FDA approved drugs and repurposed drugs are personalized to suit each patient’s unique genetic
mutations and rate of metabolism, optimizing treatment efficacy. In our clinical opinion, these personalized drugs and adjunctive agents can help in lowering
mutational loads, which is crucial in aggressive cancers like esophageal cancer.
Precision Deployment of New Treatments to Minimize Side Effects
Personalization of a unique medical blueprint for each patient’s specific esophageal cancer also includes
determining
a
suitable precision deployment mechanism for them. Our expert physicians choose the most effective precision
deployment
mechanism based on the position of the tumor, each patient’s unique genomics, and other factors influencing
their
esophageal cancer.
The precision-targeted chemo and immuno agents administered via these precision deployment mechanisms, serve as
a
powerful combination to enhance tumor kill, while bolstering immunity. Lack of this level of customization in
standard
treatment may not only fail in treating the cancer holistically, but it also causes debilitating side effects,
making
it
difficult for patients to recover from the disease.
At Envita, we overcome these challenges with our proprietary new treatments, which precision deploy our personalized
anti-cancer medications to enhance their bioavailability to the cancer cells. Increased bioavailability translates to
better absorption of the medications by the cancer cells, which improves the chances of response to treatment, and
causes negligible side effects.
Most of our medicines are administered either intravenously or through our distinctive interventional radiology
procedures. Here are some of our proprietary precision deployment mechanisms:
CIPI™ (Chemo Immuno Precision Injections)
CIPI™, a proprietary interventional radiology procedure, is one of Envita’s revolutionary esophageal cancer treatment
options, which helps in treating the cancer even when it has metastasized to inoperable regions of the body.
Esophageal
cancers with their high mutation rates can quickly metastasize to surrounding lymph nodes, which may be difficult to
reach via standard surgical options. In such cases, the CIPI™ procedure has an advantage as it utilizes a catheter,
thinner than a strand of hair, to push targeted chemotherapy and immunotherapy medications directly to the tumor.
CIPI™, a proprietary interventional radiology procedure, is one of Envita’s revolutionary esophageal cancer treatment
options, which helps in treating the cancer even when it has metastasized to inoperable regions of the body.
Esophageal
cancers with their high mutation rates can quickly metastasize to surrounding lymph nodes, which may be difficult to
reach via standard surgical options. In such cases, the CIPI™ procedure has an advantage as it utilizes a catheter,
thinner than a strand of hair, to push targeted chemotherapy and immunotherapy medications directly to the tumor.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
This proprietary form of tumor chemoembolization shuts off the tumor intratumorally, while generating a systemic
response, helping the immune system identify and kill cancer cells elsewhere in the body. In our clinical experience,
the CIPI™ procedure has shown to potentially increase tumor kill and reduce the negative side-effects related to
surgical options and traditional chemotherapy regimens. Leading edge approaches like CIPI™ are one of the many
reasons why numerous
patients are turning to Envita for new and exciting alternative options for personalized esophageal cancer treatment.
GTFC™ (Genetically Targeted Fractionated Chemotherapy) is Envita’s state-of-the-art low dose chemotherapy, which is
deployed intravenously to strike at the esophageal cancer cells, while reducing impact to the adjoining healthy cells.
With the healthy cells remaining intact, our patients rarely experience side effects, such as weakened immunity,
commonly associated with standard maximum-dose untargeted chemotherapy.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Through GTFC™, we are also able to increase the mechanisms of
action against the cancerous cells as we use metronomic dosage of a
greater number of chemo agents, than those used in standard chemotherapy. Enhancing tumor kill, while reactivating the
patient’s immune system, gives them a better chance at progressing towards a holistic recovery. A strong immune system
acts as a catalyst in the cancer treatment process, accelerating your journey towards healing.
Types of Esophageal Cancer
The following are the diverse types of esophageal cancer, which can be further divided into various sub-types
depending
on their grades and cellular characterizations:
Esophageal Adenocarcinoma: Adenocarcinomas of the esophagus start in the cells of the mucosa, which is a
soft tissue lining the inside of body’s
canals. This type of esophageal cancer usually develops in the lower part of the esophagus.
Esophageal Squamous Cell Carcinoma: Squamous cell cancer of the esophagus originates in the squamous
cells that line the surface of the esophagus. This type
of esophageal cancer usually develops in the upper or middle part of the esophagus.
Gastroesophageal Junction Cancer: This rare type of cancer can be either adenocarcinoma or squamous cell
carcinoma of the esophagus, starting in the area
where the esophagus joins the stomach.
Symptoms of Esophageal Cancer
If you have any of the following symptoms, your doctor may recommend an endoscopy, CT (Computerized Tomography)
scan,x ray, or other imaging tests, to check if you have esophageal cancer:
Envita’s expert physician team undergoes extensive training over 1,500 hours to adapt to our personalized precision
oncology program. Our cross-functional team ensures that our patients receive the expertise of medical, surgical, and
radiation oncologists as and when needed, to help in their holistic recovery. If you or any of your loved ones have
questions regarding esophageal cancer or any other type of cancer, please call us at 866-830-4576. May God bless you
on
your journey to healing!
References
[1] Luan S, Zeng X, Zhang C, et al. Advances in Drug Resistance of Esophageal Cancer: From the Perspective of
Tumor
Microenvironment. Front Cell Dev Biol. 2021;9:664816. Published 2021 Mar 19. doi:10.3389/fcell.2021.664816
[2] Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate
strategy for
individualizing medicine?. Per Med. 2011;8(2):161-173. doi:10.2217/pme.11.7
[3] Testa U, Castelli G, Pelosi E. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell
Compartment and
Clonal Evolution. Medicines (Basel). 2017;4(3):67. Published 2017 Sep 14. doi:10.3390/medicines4030067
[4] Sun J, Deng Y, Shi J, Yang W. MicroRNA5423p represses OTUB1 expression to inhibit migration and invasion of
esophageal
cancer cells. Mol Med Rep. 2020;21(1):35-42. doi:10.3892/mmr.2019.10836
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
